Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28049477 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL4565393 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL10030565 | 0.90 | NOS2 (0.42) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL23408681 | 0.90 | MEN1 (0.35) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL27496954 | 0.89 | PRCP (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL3310012 | 0.88 | PRCP (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL3310014 | 0.88 | PRCP (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL9357035 | 0.86 | PRCP (0.40) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL26117510 | 0.85 | NOS2 (0.41) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL10826223 | 0.84 | PRCP (0.46) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460826-B1 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO | DAIICHI SANKYO CO LTD (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-8710184-B2 | Motilin-like peptide compound having transmucosal absorbability imparted thereto | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-04-29 | — | — | US | disclosed |
| EP-2460826-A1 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO | Daiichi Sankyo Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129762-A1 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2134173-A2 | TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION | Advanced Vision Therapies, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008106644-A2 | TREATMENT OF DISEASES CHARACTERIZED BY INFLAMMATION | ADVANCED VISION THERAPIES, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7208577-B2 | Methods of increasing lean tissue mass using OB protein compositions | AMGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050176107-A1 | Methods of increasing lean tissue mass using OB protein compositions | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129762-A1 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO | MLNR, MLN, VIP | NOS2 1595/4885NOS3 2802/4885NOS1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.